Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840
Study Identifier:
ALXN1840-WD-204
ClinicalTrials.gov Identifier:
EudraCT Identifier:
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: ALXN1840
Date
Sep 2020 - Jun 2022
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information
Sex
Female & Male
Age
18+ years
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: ALXN1840
Date
Sep 2020 - Jun 2022
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years years
Requirements Information
Protocol Summary
This exploratory study will investigate the effects of ALXN1840 on copper balance in participants with Wilson disease (WD).
Trial Locations
Location
Status
Location
Research Site
New Haven, Connecticut, United States, 06510
Status
N/A
Location
Research Site
Grafton, New Zealand, 1010
Status
N/A
Location
Research Site
London, United Kingdom, SE1 1YR
Status
N/A